FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
By Ronald Boellaard, M. O'Doherty, W. Weber, F. Mottaghy, M. Lonsdale, S. Stroobants, W. Oyen, J. Kotzerke, O. Hoekstra, J. Pruim and 18 more. European Journal of Nuclear Medicine and Molecular Imaging, 2009
1,351 citations recorded by the source corpus.
The aim of this guideline is to provide a minimum standard for the acquisition and interpretation of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG). This guideline will therefore address general information about [18F]-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) and is provided to help the physician and physicist to assist to carrying out, interpret, and document quantitative FDG PET/CT examinations, but will concentrate on the optimisation of diagnostic quality and quantitative information.
Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/6bc6d5b8fbfe6a545529e2bbd0d54d55bee0ebd0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Radiology, Nuclear Medicine and Imaging
- Hugo J. W. L. Aerts
- Philippe Lambin
- Robert A. Gatenby
- Robert James Gillies
- Chintan Parmar
- Ahmed Hosny
Citations in the corpus
- Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. (2014, methodology): “general application.(38,39,41,51-53,121,140) The optimum cutoff is also”
- QIN “Radiomics: The Process and the Challenges” (2012, methodology): “Before a scanner is used in a quantitative manner, interinstitution cross-calibration and quality control such as proposed recently [14] are necessary (Fig.”
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 (2014, neutral): “• The effects of growth factors (G-CSF and GM-CSF) on FDG biodistribution (due to enhanced bone marrow uptake) generally last for more than 2 weeks after the final administration [20].”